ASCLETIS PHARMA INC.

Insiders Ascletis Pharma Inc.

Equities

1672

KYG0520K1094

Market Closed - Hong Kong S.E. Other stock markets 01:38:11 08/05/2024 pm IST			5-day change	1st Jan Change
1.36 ^HKD	-2.86%		-2.86%	-6.85%

03/04	Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus	MT
03/04	Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42	CI

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ascletis Pharma Inc. Appoints John P. Gargiulo as Chief Business Officer	13/22/13	CI
Ascletis Pharma Inc. Announces Board Changes	30/20/30	CI
Ascletis Pharma Inc. Appoints Former Novartis Global Head Dr. Handan He as Chief Scientific Officer	08/19/08	CI
Ascletis Pharma Inc. Announces the Resignation of Joint Company Secretary and Change of Authorized Representative	13/19/13	CI
Ascletis Pharma Inc. Appoints Zhengqing Li as Chief Medical Officer and President of R&D Greater China	01/19/01	CI
Ascletis Pharma Announces Resignation of Wei Fu as Non-Executive Director	24/18/24	CI
Ascletis Pharma Inc. Appoints Dr. Lindi Tan as Chief Financial Officer	12/18/12	CI
Ascletis Pharma Inc. Appoints Joshua Zhongbao Ling as Vice President of Finance	30/18/30	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW